Although not statistically significant, the gE-specific IFN-γ produced CD4+ T cells, which are more frequently adopted than CD8+ T cells as good indicators for the potential of zoster vaccines in animal experiments and clinical trials, at approximately 2.84 times the quantity of the AS01B adjuvanted subunit vaccines, which was consistent with the result of a 573 aa carboxyl-terminal truncated and Y569A-mutated gE mRNA vaccine tested in nonhuman primates [17,23,44]. The gene discussed is CD4; the disease is herpes zoster.